Torsten Dreier

TLDR

Torsten Dreier is a co-founder of argenx, the Ghent-based NASDAQ-listed biotech company focused on autoimmune disease treatments.

Overview

Torsten Dreier co-founded argenx in 2008 in Ghent alongside Tim Van Hauwermeiren and Hans de Haard, having previously worked together at Ablynx. He has more than 20 years of antibody development experience and progressed six antibody products from preclinical research into clinical trials. At Ablynx he held roles as Director of Therapeutic Drug Development and Senior Director Preclinical Development.